Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma

Disclosures: LG, SO and MJ report employment in Novartis Pharmaceuticals. EMO, RGS, JFSM and MVM report consultancy for Novartis Pharmaceuticals.

Contributions: EMO, JD, JCB, SA, VGC, RGS, JFSM and MVM took care of the patients reported. EMO and JD wrote the initial draft of the manuscript. LG, SO and MJ participated in the design of the trial in which the patients were included. All authors contributed to the final version of the paper and provided their comments.